Skip to main content

Table 2 Drug repositioning candidates for Alzheimer’s disease (AD). Drugs showing a negative correlation score less than or equal to −0.40 and affecting more than 50% of the dysregulated pathways in AD

From: PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures

DrugDrugBank IDCorrelation ScoreAffected Pathways (%)
Sirolimus (Rapamycin)DB00877−0.6966.67
PevonedistatDB11759−0.6660.61
NilotinibDB04868−0.6460.61
TerfenadineDB00342−0.5757.58
Doxylamine SuccinateDB00366−0.5754.55
HalcinonideDB06786−0.5751.52
Promazine HydrochlorideDB00420−0.5366.67
MosaprideDB11675−0.4560.61
PimozideDB01100−0.4557.58
RitanserinDB12693−0.4557.58
BetamethasoneDB00443−0.4466.67
Cinacalcet HydrochlorideDB01012−0.4372.73
Methapyrilene HydrochlorideDB04819−0.4372.73
TrametinibDB08911−0.4060.61